Keratoacanthoma and squamous cell carcinoma: Study of PCNA and Le(Y) expression

Journal of Cutaneous Pathology

Volumn 24, Issue 7, 1997, Pages 409-415

  Tsuji, Takuo ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BLOOD GROUP LEWIS SYSTEM; CLINICAL ARTICLE; EPIDERMIS; ETIOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATOACANTHOMA; MALE; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATOACANTHOMA; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; SKIN NEOPLASMS;

EID: 0030858047     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1997.tb00815.x     Document Type: Article

References (57)

1. Ackerman AB, Mendonça AMN, Guo Y. Keratoacanthoma vs squamous-cell carcinoma. In: Differential diagnosis in dermatopathology I. 2nd edn. Philadelphia/London: Lea & Febiger, 1992: 122.
2. Schwartz RA. Continuing medical education keratoacanthoma. J Am Acad Dermatol 1994: 30: 1.
3. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993: 15: 332.
4. Inverson RE, Vistnes LM. Keratoacanthoma is frequently a dangerous diagnosis. Am J Surg 1973: 126: 359.
5. Connors RC, Ackerman AB. Histologic pseudomalignancies of the skin. Arch Dermatol 1976: 112: 1767.
6. Schnur PL, Bozzo P. Metastasizing keratoacanthoma? Plast Reconst Surg 1978: 12: 258.
7. Herzberg AJ, Kerns BJ, Pollack SB, et al. DNA image cytometry of keratoacanthoma and squamous cell carcinoma. J Invest Deramtol 1991: 97: 495.
8. Pilch H, Weiss J, Heubner C, Heine M. Differential diagnosis of keratoacanthomas and squamous cell carcinomas: diagnostic value of DNA image cytometry and p53 expression. J Cutan Pathol 1994: 21: 507.
9. Kannon G, Park HK. Utility of peanut agglutin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma. Am J Dermatopathol 1990: 12: 31.
10. Korenberg R, Penneys NS, Kowalczyk, et al. Quantitation of S100 protein-positive cells in inflamed and non-indurated keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1988: 15: 104.
11. Kanitakis J, Hoyo E, Hermier C, et al. Nucleolar organizer region enumeration in keratoacanthomas and squamous cell carcinomas of the skin. Cancer 1992: 69: 2937.
12. Miracco D, De Santi MM, Lio R, et al. Quantitatively evaluated ultrastructural findings can add to the differential diagnosis between keratoacanthoma and well differentiated squamous cell carcinoma. J Submicrosc Cytol Pathol 1992: 24: 315.
13. Klein-Szanto AJP, Barr RJ, Reiners JJ, et al. Filaggrin distribution in keratoacanthomas and squamous cell carcinoma. Arch Pathol Lab Med 1984: 108: 888.
14. Schaumburg-Lever G, Alroy J, Gavris V, et al. Cell-surface carbohydrates in proliferative epidermal lesions: distribution of A, B and M blood group antigens in benign and malignant lesions. Am J Dermatopathol 1984: 6: 583.
15. Ho T, Horn T, Finzi E. Transforming growth factor a expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol 1991: 127: 1167.
16. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994: 130: 181.
17. Skálová A, Michal M. Pattern of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of skin. Immunohistochemical study using the MIR1 antibody in formalin-fixed, paraffin-embedded sections. Am J Dermatopathol 1995: 17: 332.
18. Matsuta M, Kimura S, Kosegawa G, Kon S, Matsuta M. Immunohistochemical detection of Ki-67 in epithelial skin tumor in formalin-fixed paraffin-embeded tissue sections using a new monoclonal antibody (MIB-1). J Dermatol 1996: 23: 147.
19. Saida T, Dohi S, Sadaki M, et al. Distribution pattern and frequency of proliferating cells in cutaneous keratinocytic neoplasms. J Am Acad Dermatol 1992: 26: 744.
20. Geary WA, Cooper PH. Proliferating cell nuclear antigen in common epidermal lesions. J Cutan Pathol 1992: 19: 458.
21. Penneys NS, Bogaert M, Serfling U, Sisto M. PCNA expression in cutaneous keratinous neoplasms and verruca vulgaris. Am J Pathol 1992: 141: 139.
22. Phillips P, Helm KF. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1993: 20: 424.
23. Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol 1995: 17: 324.
24. Sleater JP, Beers BB, Stephens CA, Hendricks JB. Keratoacanthoma: a deficient squamous cell carcinoma? Study of bcl-2 expression. J Cutan Pathol 1994: 21: 514.
25. Stephenson TJ, Royds J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992: 127: 566.
26. Lee Y-S, Teh M. P53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer 1994: 73: 2317.
27. Ro YS, Cooper PN, Lee JA, et al. p53 protein expression in benign and malignant skin tumours. Br J Dermatol 1993: 128: 237.
28. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993: 29: 741.
29. Lowry WS, Atkinson RJ. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1993: 128: 708.
30. Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol 1994: 102: 440.
31. Borkowskin A, Bennett WP, Jones RT, et al. Quantitative image analysis of p53 protein accumulation in keratoacanthomas. Am J Dermatopathol 1995: 17: 335.
32. Weedon D, Searle J, Kerr JFR. Apoptosis: its nature and implications for dermatopathology. Am J Dermatol 1979: 1: 133.
33. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci USA 1985: 82: 3262.
34. Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989; 264: 13856.
35. Moore KS, Sullivan K, Tan EM, Prystowsky MB. Proliferating cell nuclear antigen/cyclin is an interleukin 2-responsitive gene. J Biol Chem 1987: 262: 8447.
36. Y) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histologic types of colonic polyps, and adenocarcinoma. Cancer Res 1986: 46: 2639.
37. Y blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 1986: 46: 5985.
38. 6). J Biol Chem 1986: 49: 745.
39. Y antigen in human immunodeficiency virus-infected human T cell lines and in peripheral lymphocytes of patients with acquired immune defficiency syndrome (AIDS) and AIDS-related complex (ARC). J Exp Med 1988: 167: 323.
40. Y antigen expresison in the CD8 subpopulation in peripheral blood of patients with viral hepatitis. In: Hollinger FB, Lemon SM, Margolis HS, eds. Proceedings of the 1990 international symposium on viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991: 289.
41. Y antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993: 3: 381.
42. Zhang W, Naomoto Y, Tanaka N, et al. Synergistic effect of tumor necrosis factor-α and interferon-α on the induction of apoptosis detected by BM-1/JIMRO: a new marker of apoptosis. Acta Med Okayama 1994: 48: 51.
43. Y and nick-end labeling are positive in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol 1994: 88: 209.
44. Y antigen expression by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line. Acta Histochem Cytochem 1994: 27: 591.
45. Y and bcl-2 protein in non-Hodgkin's lymphomas. Pathol Int 1995: 45: 422.
46. Y antigen, apoptosis and differentiation in human lung cancer cells. Anticancer Res 1995: 15: 2137.
47. Y antigen by 5-aza-2′-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Anticancer Res 1996: 16: 735.
48. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993: 53: 1945.
49. Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 1992: 207: 163.
50. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: a historical perspective. In: Tomei LD, Copa FO, eds. Apoptosis: The molecular basis of cell deth. Current communications in cell and nuclear biology. N. Y.: Cold Spring Habor Laboratory Press, 1991.
51. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990: 335: 675.
52. Bartek J, Iggo R, Gannon J, et al. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990: 5: 893.
53. Zambetti, GP, Levine AJ. A comparison of the biologic activities of wild-type and mutant p53. FASEB J 1993: 7: 855.
54. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991: 65: 1097.
55. Hockenbery DM, Zutter M, Hickey W, et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Nad Acad Sci USA 1991: 88: 6961.
56. Verhaegh MEJM, Sanders CJG, Arends JW, et al. Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. Br J Dermatol 1995: 132: 740.
57. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993: 101: 107.